Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Nova Mentis Life Science Corp. C.LIB

Nova Mentis Life Science Corp is a Canadian-based company focused on building and supporting a diversified portfolio of health and wellness businesses. Through its subsidiary, the company is focused on exploring the anti-inflammatory effects of psilocybin in underexplored metabolic indications such as obesity and diabetes and providing a Health Canada Standard Licensed facility focused on the... see more

CSE:LIB - Post Discussion

Nova Mentis Life Science Corp. > $1 after license!
View:
Post by DeanCraig on Oct 13, 2018 12:24pm

$1 after license!

You will See $1 after license! There’s so much more upside especially with JK completion.
Comment by michelleb33 on Oct 13, 2018 12:50pm
your prediction is not as overblown as some posters on here. Ok pump a dollar and sell at 25 cents right. I get it .play on
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities